# Hematopoiesis and Hematological Malignancies Program

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $32,123

## Abstract

ABSTRACT, Hematopoiesis and Hematologic Malignancies Program (HHM)
Based on the robust basic mechanistic studies performed by our members that resulted in consecutive
outstanding scores for the last four NCI site visits, HHM is now a basic science Program whose ultimate goal is
to advance treatment of hematologic malignancies and disorders through rigorous basic scientific laboratory
efforts. Our goal is to gain mechanistic insight into malignant cell processes, how they differ from normal
processes through interactions with the TMM Program, and to provide this information with our guidance to the
EDT and CPC programs for translation for clinical utility and health benefit to modulate and slow disease
progression, with the ultimate goal of curing malignant diseases. Our Program has two areas of focus:
Hematopoiesis (H) and Hematologic Malignancy (HM) themes. The H-theme includes: characterization of
human and mouse hematopoietic stem (HSC) and progenitor (HPC) cells and their mechanistic regulation,
understanding the biology of cytokine/chemokine actions, including cells of the hematopoietic microenvironment
and the immune systems and their interactions that regulate HSC and HPC functions; this includes proliferation,
survival, self-renewal, differentiation, mobilization and engraftment for hematopoietic cell transplantation (HCT)
and biomarker/biomolecule assessment for predicting and modulating graft vs host disease after HCT without
adversely modulating graft vs. leukemia/tumor effects. The HM-theme is focused on understanding and
modifying the biology of leukemia/myeloma (including leukemia stem cells) and bone cell interactions (especially
for multiple myeloma), including intracellular events mediating the function and interactions of these cells. The
Program has two highly interactive co-leaders: Broxmeyer and Roodman, both with national and international
reputations and who have a deep and long history of research in hematopoiesis and hematologic malignancies.
HHM has a total of 17 Full and 7 Associate interactive members from 6 different Departments of the IU School
of Medicine. Our Program members have published 304 papers during the past CCSG funding period, of which
25% are intra-programmatic, 17% are inter-programmatic, and 65% are multi-institutional, with 32% of these
publications in journals with an impact factor ranging from 9 to greater than 40. The total (direct cost) of external
peer-reviewed funding and NCI funding are respectively $7.6M and $1.17M with the current funding per Full
member currently at $448K. The Program also has three NIH T32 Training grants (DK007519, HL007910, and
AI060519) at $733.3K, and a U54 Cooperative Center of Excellence in Hematology (DK106846). Our Program
has greatly benefited from IUSCC through: pilot-funding, core facilities, sponsored seminar series, cancer grand
rounds and with numerous formal and informal intra- and inter-programmatic meetings. Collectively, these have
enhanced our capacity fo...

## Key facts

- **NIH application ID:** 10247614
- **Project number:** 5P30CA082709-22
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** HAL E. BROXMEYER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $32,123
- **Award type:** 5
- **Project period:** 1999-09-22 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10247614

## Citation

> US National Institutes of Health, RePORTER application 10247614, Hematopoiesis and Hematological Malignancies Program (5P30CA082709-22). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10247614. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*